Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Jim Roof who wrote (2070)	7/13/1999 6:53:00 PM
From: Kevin Podsiadlik	Read Replies (2) \| Respond to of 10293

Not to burst your bubble but the heaviest of the heavies is in Biotime's corner, Abbott Labs Speaking of burst bubbles, weren't they the ones that, upon Hextend's approval, affirmed the claims of short-sellers by announcing that its anticipated market was a small fraction of what Biotime, or more precisely its "all-knowing" analysts, were claiming it to be?

To: Jim Roof who wrote (2070)	7/14/1999 3:27:00 PM
From: Marconi	Respond to of 10293

Hello Mr. Roof: BTIM I see your point of view. I meant the 25 to 6 drop in the last year and the 18 downward trend of present. Obviously I am expecting the downtrend to continue this time to under 6, probably the 4-5 range where shorting becomes difficult for many folks and many will have boxed or covered by then. There is no substitute for performance and I do not expect Biotime to earn market cap in the year forward. A fair start would be to see reported significant replacement sales (not stocking inventory). The other large med supply firm in the Chicago area is major in IV solutions and bric-a-brac hospital supplies. I am sorry I do not remember the name. They have their Renal Systems division in the Chicago area--one of my lower classmates may be running much of it yet. Anyway, that firm in the early 90's was contracting hospitals to do their supply management through computerization with them. It reminded me of the airlines reservation system. However, there was no preference given for the firm's products--at least not at that time. I thought they had something like 60% of the beds covered at one time. The neat thing about that would be it would give that firm a goldmine in competitor intelligence knowing the consumption rates, inventories, and pricing of all products in use in a hospital. I thought the other firm rather than Abbott was the larger in IV solutions. I discount Abbott's involvement--important to BTIM, yes, but much less important to Abbott. And no shoo-in if a competitor such as the other firm (not Abbott) were to reformulate a line of solutions if there is found to be any significant business to be had with starch solutions. Best regards, m